MY197265A - Methods and compositions for soft anticholinergic esters - Google Patents

Methods and compositions for soft anticholinergic esters

Info

Publication number
MY197265A
MY197265A MYPI2018700940A MYPI2018700940A MY197265A MY 197265 A MY197265 A MY 197265A MY PI2018700940 A MYPI2018700940 A MY PI2018700940A MY PI2018700940 A MYPI2018700940 A MY PI2018700940A MY 197265 A MY197265 A MY 197265A
Authority
MY
Malaysia
Prior art keywords
soft anticholinergic
compositions
methods
sialorrhea
intra
Prior art date
Application number
MYPI2018700940A
Other languages
English (en)
Inventor
Nicholas S Bodor
Original Assignee
Bodor Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodor Laboratories Inc filed Critical Bodor Laboratories Inc
Publication of MY197265A publication Critical patent/MY197265A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2018700940A 2015-09-11 2016-09-06 Methods and compositions for soft anticholinergic esters MY197265A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562217362P 2015-09-11 2015-09-11
PCT/US2016/050385 WO2017044412A1 (en) 2015-09-11 2016-09-06 Methods and compositions for soft anticholinergic esters

Publications (1)

Publication Number Publication Date
MY197265A true MY197265A (en) 2023-06-08

Family

ID=58239861

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018700940A MY197265A (en) 2015-09-11 2016-09-06 Methods and compositions for soft anticholinergic esters

Country Status (13)

Country Link
US (3) US11534422B2 (enExample)
EP (1) EP3347007B1 (enExample)
JP (4) JP7270958B2 (enExample)
KR (1) KR102889909B1 (enExample)
CN (4) CN118045082A (enExample)
AU (2) AU2016318595B2 (enExample)
CA (1) CA2998357A1 (enExample)
ES (1) ES2942361T3 (enExample)
IL (1) IL257970B (enExample)
MX (1) MX388831B (enExample)
MY (1) MY197265A (enExample)
WO (1) WO2017044412A1 (enExample)
ZA (1) ZA201801685B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044965A (zh) * 2018-10-17 2018-12-21 广州大光制药有限公司 格隆溴铵的眼用药物组合物及医药用途
US20230149349A1 (en) * 2020-03-03 2023-05-18 Kaken Pharmaceutical Co., Ltd. Medicament containing sofpironium bromide
KR20240088983A (ko) 2021-11-01 2024-06-20 유타대학연구재단 침흘림증 치료를 위한 조성물 및 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
WO2001008681A1 (en) 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
EP1845979A4 (en) 2005-01-19 2009-11-11 Neurohealing Pharmaceuticals I METHOD AND COMPOSITIONS FOR REDUCING STORAGE PRODUCTION
CA2627982C (en) 2005-11-10 2013-09-10 Nicholas S. Bodor Soft anticholinergic esters
US7399861B2 (en) 2005-11-10 2008-07-15 Bodor Nicholas S Soft anticholinergic esters
US8071693B2 (en) 2006-06-22 2011-12-06 Sabic Innovative Plastics Ip B.V. Polysiloxane/polyimide copolymers and blends thereof
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP2010530902A (ja) 2007-06-22 2010-09-16 サイエル ファーマ,インコーポレイティド 流涎症治療のためのグリコピロレートを含む経皮送達システム
US8628729B2 (en) 2008-03-27 2014-01-14 President And Fellows Of Harvard College Three-dimensional microfluidic devices
JP6223543B2 (ja) 2013-03-15 2017-11-01 ボドール ラボラトリーズ, インコーポレイテッド 多汗症の処置のための抗コリン作用性グリコピロレートエステル

Also Published As

Publication number Publication date
JP2023164671A (ja) 2023-11-10
KR20180061220A (ko) 2018-06-07
WO2017044412A1 (en) 2017-03-16
JP2018526420A (ja) 2018-09-13
JP7270958B2 (ja) 2023-05-11
US11534422B2 (en) 2022-12-27
MX388831B (es) 2025-03-20
AU2021204306B2 (en) 2023-11-09
JP7723417B2 (ja) 2025-08-14
ES2942361T3 (es) 2023-05-31
AU2021204306A1 (en) 2021-07-22
JP2022132446A (ja) 2022-09-08
CN108348502A (zh) 2018-07-31
EP3347007B1 (en) 2023-03-29
IL257970B (en) 2021-04-29
ZA201801685B (en) 2023-12-20
MX2018003002A (es) 2018-08-01
US12458625B2 (en) 2025-11-04
CN118021770A (zh) 2024-05-14
IL257970A (en) 2018-05-31
CN118021797A (zh) 2024-05-14
EP3347007A4 (en) 2019-05-08
CA2998357A1 (en) 2017-03-16
US20220401410A1 (en) 2022-12-22
JP2021001238A (ja) 2021-01-07
AU2016318595B2 (en) 2021-07-08
KR102889909B1 (ko) 2025-11-24
CN118045082A (zh) 2024-05-17
EP3347007A1 (en) 2018-07-18
HK1255558A1 (en) 2019-08-23
US20180250265A1 (en) 2018-09-06
US20240261262A1 (en) 2024-08-08
US11951093B2 (en) 2024-04-09
AU2016318595A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
PH12016501732B1 (en) Formulation for soft anticholinergic analogs
PH12018500184A1 (en) Formulation for soft anticholinergic analogs
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
MX2022001292A (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos.
PH12014501656B1 (en) Compositions and methods of use of phorbol esters for the treatment of stroke
PH12019500142A1 (en) Formulation for soft anticholinergic analogs
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
WO2017019540A3 (en) Inhibitors of n-linked glycosylation and methods using same
SG11202009522TA (en) Compositions and methods for long lasting disinfection
SG11202009523UA (en) Compositions and methods for long lasting disinfection
PH12014000195B1 (en) Composition of medium chain triglycerides containing substantial amount of lauric acid
SG10201909382UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
PH12016500910A1 (en) Long-acting ketoprofen compositions
ZA201801685B (en) Methods and compositions for soft anticholinergic esters
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
WO2015044317A3 (en) Staphylococcus haemolyticus inhibitors for preventing and/or treating atopic dermatitis
IL291201A (en) Neurotoskin preparations for the treatment of gastroparesis
IL280569A (en) Methods and compositions for the treatment of ultraviolet radiation damage b
PT3270695T (pt) Composições herbicidas compreendendo isoxaflutol e diflufenican como únicos ingredientes herbicidas ativos
UA91070U (uk) Спосіб профілактики та корекції запальних захворювань на донозологічному рівні
UA101533U (uk) Полівалентний оральний гель для лікування і профілактики післяімплантаційних ускладнень
WO2016029158A3 (en) Compositions and methods for extending lifespan